Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31131399 | 0.71 | HTR2C (0.58) | HTR2CGABRA1GABRB2QDPRHTR6 | |
| SCHEMBL13749404 | 0.71 | HTR2C (0.58) | HTR2CGABRA1GABRB2QDPRHTR6 | |
| SCHEMBL19347098 | 0.71 | HTR2C (0.58) | HTR2CGABRA1GABRB2QDPRHTR6 | |
| SCHEMBL25817270 | 0.70 | HTR2C (0.42) | HTR2CGABRA1GABRB2HTR6SLC6A2 | |
| SCHEMBL21808459 | 0.70 | KDM4E (0.42) | — | |
| SCHEMBL25817289 | 0.70 | HTR2C (0.42) | HTR2CGABRA1GABRB2HTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL25328473 | 0.70 | HTR2C (0.59) | HTR2CGABRA1GABRB2QDPRHTR6 | |
| Hydrochloric Acid SCHEMBL30493296 | 0.70 | HTR2C (0.59) | HTR2CGABRA1GABRB2QDPRHTR6 | |
| SCHEMBL10698817 | 0.69 | KDM4E (0.41) | — | |
| SCHEMBL11705589 | 0.69 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | HTR2C 374/4885GABRA1 328/4885GABRB2 432/4885 |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | HTR2C 374/4885GABRA1 328/4885GABRB2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.